Rebamipide

Catalog No.S2032 Synonyms: OPC-12759

For research use only.

Rebamipide (OPC-12759) is a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [125I]BH-CCK-8S with IC50 of 37.7 μM.

Rebamipide Chemical Structure

CAS No. 90098-04-7

Selleck's Rebamipide has been cited by 2 Publications

Purity & Quality Control

Choose Selective CCK receptor Inhibitors

Biological Activity

Description Rebamipide (OPC-12759) is a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [125I]BH-CCK-8S with IC50 of 37.7 μM.

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 74 mg/mL
(199.57 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 370.79
Formula

C19H15ClN2O4

CAS No. 90098-04-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04150172 Completed Drug: Rebamipide SR 150mg|Drug: Rebamipide IR 100mg Healthy Volunteers Korea Otsuka Pharmaceutical Co. Ltd. April 22 2019 Phase 1
NCT02106130 Completed Drug: Rebamipide|Drug: Mosapride citrate Healthy IlDong Pharmaceutical Co Ltd May 2013 Phase 1
NCT01167101 Completed Drug: Rebamipide|Drug: pantoprazole Stomach Ulcer Kangdong Sacred Heart Hospital May 2009 Not Applicable
NCT00997789 Completed Drug: Rebamide Therapeutic Equivalency|Pharmacogenetics Chonnam National University Hospital|Institute of Bioequivalence and Bridging Study College of Pharmacy CNU March 2008 Not Applicable
NCT00996788 Completed Drug: Rebamipide Dyspepsia|Chronic Gastritis PT Otsuka Indonesia October 2007 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Rebamipide | Rebamipide supplier | purchase Rebamipide | Rebamipide cost | Rebamipide manufacturer | order Rebamipide | Rebamipide distributor